ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use Initial U.S. Approval: 2019

Category: .

ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use Initial U.S. Approval: 2019

INDICATIONS AND USAGE
Ontruzant is a HER2/neu receptor antagonist indicated for:
• The treatment of HER2-overexpressing breast cancer.
• The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
DOSAGE FORMS & STRENGTHS
For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution.
• For Injection: 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
Manufactured By: Merck Sharp & Dohme Corp.
Prescribing Information URL: Click Here

Access to ONTRUZANT (trastuzumab-dttb) for injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Trastuzumab-dttb was first approved as a 150 mg single-dose vial by the FDA in January 2019 across all eligible indications, mainly adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.
Trastuzumab-dttb is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, including:
• As a part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel.
• With docetaxel and carboplatin.
• As a single agent following multi-modality anthracycline-based therapy.
In addition, trastuzumab-dttb is indicated in combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer and as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.